Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier

Drug Delivery

Volumn 17, Issue 7, 2010, Pages 552-558

  Tang, Hong Bo ^a   Li, Lei ^a   Chen, Han ^a   Zhou, Zhi Min ^a   Chen, Hong Li ^a   Li, Xue Min ^a   Liu, Ling Rong ^a   Wang, Yin Song ^c   Zhang, Qi Qing ^a,b  

^a INSTITUTE OF BIOMEDICAL ENGINEERING   (China)

^b XIAMEN UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Epirubicin; Nanoparticles; Pharmacokinetics; Pullulan acetate; Toxicity

Indexed keywords

EPIRUBICIN; NANOCARRIER; PULLULAN; PULLULAN ACETATE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; EVALUATION; FEMALE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SAFETY; SINGLE DRUG DOSE; SYNTHESIS; ZETA POTENTIAL;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG STABILITY; EPIRUBICIN; FEMALE; GLUCANS; HALF-LIFE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; RATS; RATS, WISTAR; SOLUBILITY;

EID: 77956166055     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.490250     Document Type: Article

References (37)

1. Akiyoshi, K., Moriguchi, N., Yamaguchi, S., Sunamoto, J. (1993). Self-aggregates of hydrophobized polysaccharides in water. Formation and characteristics of nanoparticles. Macromolecules. 26:3062-3068
2. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C. (2008). Factors afecting the clearance and biodistribution of polymeric nano-particles. Mol Pharm. 5:505-515
3. Bibby, D.C., Talmadge, J.E., Dalal, M.K., Kurz, S.G., Chytil, K.M., Barry, S.E., Shand, D.G., Steiert, M. (2005). Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparti-cles in tumor-bearing mice. Int J Pharm. 293:281-290
4. Bilati, U., Allemann, E., Doelker, E. (2005). Development of a nano-precipitation method intended for the entrapment of hydrophilic drugs into nanoparticles. Eur J Pharm Sci. 24:67-75.
5. Cao, N., Feng, S.S. (2008). Doxorubicin conjugated to D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS): conjugation chemistry, characterization, in vitro and in vivo evaluation. Biomaterials. 29:3856-3865
6. Curtis, J., Greenberg, M., Kester, J., Phillips, S., Krieger, G. (2006). Nanotechnology and nanotoxicology: a primer for clinicians. Toxicol Rev. 25:245-260
7. Dai, W., Zhang, D., Duan, C., Jia, L., Wang, Y., Feng, F., Zhang, Q. (2010). Preparation and characteristics of oridonin-loaded nanostructured lipid carriers as a controlled-release delivery system. J Microencapsul. 27:234-241
8. Devalapally, H., Rajan, K.S., Akkinepally, R.R., Devarakonda, R.K. (2008). Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy. Drug Dev Ind Pharm. 34:789-795
9. Fessi, H., Puisieux, F., Devissaguet, J.P., Ammoury, N., Benita, S. (1989). Nanocapsule formation by interfacial deposition following solvent displacement. Int J Pharm. 55:R1-R4.
10. Fischer, H.C., Chan, W.C. (2007). Nanotoxicity: the growing need for in vivo study. Curr Opin Biotechnol. 18:565-571
11. Govender, T., Stolnik, S., Garnett, M.C., Illum, L., Davis, S.S. (1999). PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Contr Rel. 57:171-185
12. Gu, X.G., Schmitt, M., Hiasa, A., Nagata, Y., Ikeda, H., Sasaki, Y., Akiyoshi, K., Sunamoto, J., Nakamura, H., Kuribayashi, K., Shiku, H. (1998). A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 58:3385-3390
13. Gustafson, D.L., Rastatter, J.C., Colombo, T., Long, M.E. (2002). Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 91:1488-1501
14. Jakobsen, P., Sorensen, B., Bastholt, L., Mirza, M.R., Gjedde, S.B., Mouridsen, H.T., Rose, C. (1994). The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fuorouracil, and tamoxifen in meta-static breast-cancer patients. Cancer Chemoth Pharm. 35:45-52.
15. Jakobsen, P., Steiness, E., Bastholt, L., Dalmark, M., Lorenzen, A., Petersen, D., Gjedde, S.B., Sandberg, E., Rose, C., Nielsen, O.S., et al. (1991). Multiple-dose pharmacokinetics of epirubicin at four diferent dose levels: studies in patients with metastatic breast cancer. Cancer Chemoth Pharma. 28:63-68
16. Jeong, Y.I., Na, H.S., Oh, J.S., Choi, K.C., Song, C.E., Lee, H.C. (2006). Adriamycin release from self-assembling nanospheres of poly(DL-lactide-co-glycolide)-grafted pullulan. Int J Pharm. 322:154-160
17. Jung, S.W., Jeong, Y.I., Kim, S.H. (2003). Characterization of hydro-phobized pullulan with various hydrophobicities. Int J Pharm. 254:109-121
18. Lanone, S., Boczkowski, J. (2006). Biomedical applications and potential health risks of nanomaterials: molecular mechanisms. Curr Mol Med. 6:651-663
19. Leathers, T.D. (2003). Biotechnological production and applications of pullulan. Appl Microbiol Biotechnol. 62:468-473
20. Levchenko, T.S., Rammohan, R., Lukyanov, A.N., Whiteman, K.R., Torchilin, V.P. (2002). Liposome clearance in mice: the efect of a separate and combined presence of surface charge and polymer coating. Int J Pharm. 240:95-102.
21. Li, S.D., Huang, L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 5:496-504.
22. Lourenco, C., Teixeira, M., Simoes, S., Gaspar, R. (1996). Steric stabilization of nanoparticles: size and surface properties. Int J Pharm. 138:1-12.
23. Medina, C., Santos-Martinez, M.J., Radomski, A., Corrigan, O.I., Radomski, M.W. (2007). Nanoparticles: pharmacological and toxicological signifcance. Br J Pharmacol. 150:552-558
24. Mross, K., Maessen, P., van der Vijgh, W.J., Gall, H., Boven, E., Pinedo, H.M. (1988). Pharmacokinetics and metabolism of epi-doxorubicin and doxorubicin in humans. J Clin Oncol. 6:517-526
25. Müller, R.H., Jacobs, C. (2002). Buparvaquone mucoadhesive nano-suspension: preparation, optimisation and long-term stability. Int J Pharm. 237:151-161
26. Na, K., Bum Lee T., Park, K.H., Shin, E.K., Lee, Y.B., Choi, H.K. (2003). Self-assembled nanoparticles of hydrophobically-modifed polysaccharide bearing vitamin H as a targeted anti-cancer drug delivery system. Eur J Pharm Sci. 18:165-173
27. Na, K., Lee, K.H., Bae, Y.H. (2004). pH-sensitivity and pH-dependent interior structural change of self-assembled hydrogel nanopar-ticles of pullulan acetate/oligo-sulfonamide conjugate. J Cont Rel. 97:513-525
28. Park, K.H., Song, H.C., Na, K., Bom, H.S., Lee, K.H., Kim, S., Kang, D., Lee, D.H. (2007). Ionic strength-sensitive pullulan acetate nano-particles (PAN) for intratumoral administration of radioisotope: ionic strength-dependent aggregation behavior and (99m) Technetium retention property. Colloids Surf B Biointerfaces. 59:16-23.
29. Rekha, M.R., Sharma, C.P. (2007). Pullulan as a promising biomaterial for biomedical applications: a perspective. Trends Biomater Artif Organs. 20:116-121
30. Seymour, L.W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K., Duncan, R. (1995). Infuence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur J Cancer. 31:766-770
31. Shimizu, T., Kishida, T., Hasegawa, U., Ueda, Y., Imanishi, J., Yamagishi, H., Akiyoshi, K., Otsuji, E., Mazda, O. (2008). Nanogel DDS enables sustained release of IL-12 for tumor immuno-therapy. Biochem Biophys Res Commun. 367:330-335
32. Shingel, K.I. (2004). Current knowledge on biosynthesis, biological activity, and chemical modifcation of the exopolysaccharide, pullulan. Carbohydr Res. 339:447-460
33. Sonaje, K., Lin, Y.H., Juang, J.H., Wey, S.P., Chen, C.T., Sung, H.W. (2009). In vivo evaluation of safety and efcacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials. 30:2329-2339
34. Tsuchihashi, M., Harashima, H., Kiwada, H. (1999). Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. J Contr Rel. 61:9-19.
35. Vega-Villa, K.R., Takemoto, J.K., Yanez, J.A., Remsberg, C.M., Forrest, M.L., Davies, N.M. (2008). Clinical toxicities of nanocar-rier systems. Adv Drug Deliv Rev. 60:929-938
36. Yoksan, R., Chirachanchai, S. (2008). Amphiphilic chitosan nano-sphere: studies on formation, toxicity, and guest molecule incorporation. Bioorg Med Chem. 16:2687-2696
37. Zhang, H.Z., Gao, F.P., Liu, L.R., Li, X.M., Zhou, Z.M., Yang, X.D., Zhang, Q.Q. (2009). Pullulan acetate nanoparticles prepared by solvent difusion method for epirubicin chemotherapy. Colloids Surf B Biointerfaces. 71:19-26.